Tags

Type your tag names separated by a space and hit enter

Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Expert Rev Neurother. 2019 04; 19(4):293-299.ER

Abstract

INTRODUCTION

Levodopa-induced dyskinesia (LID) is a significant impediment to the long-term use of levodopa for Parkinson's disease (PD). Relatively few studies exist that have described safe and effective therapy for LID. There is thus a significant need for therapy that can control LID to allow for greater sustainability of levodopa therapy. Amantadine extended release (ER) is currently the only FDA-approved medication for the treatment of LID. While other medications have demonstrated efficacy in treating the motor symptoms of PD, amantadine ER is the only one that has been shown, in several clinical trials, to reduce LID and reduce OFF time. Areas Covered: In this review, the authors present the findings of amantadine ER including its efficacy and safety. The authors also provide their expert perspectives on its use and its future prospects. Expert opinion: Several therapies are currently being used and studied for controlling LID, an unmet need in therapy for PD. Amantadine ER has potential to supplement levodopa therapy in PD and improve patient therapeutic outcomes.

Authors+Show Affiliations

a Department of Neurology , Loma Linda University School of Medicine , Loma Linda , CA , USA.a Department of Neurology , Loma Linda University School of Medicine , Loma Linda , CA , USA. b Department of Neurological Surgery , Keck School of Medicine of USC , Los Angeles , CA , USA.c Department of Neurology , University of Kansas Medical Center , Kansas City , KS , USA.c Department of Neurology , University of Kansas Medical Center , Kansas City , KS , USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30892103

Citation

Dashtipour, Khashayar, et al. "Extended-Release Amantadine for Levodopa-Induced Dyskinesia." Expert Review of Neurotherapeutics, vol. 19, no. 4, 2019, pp. 293-299.
Dashtipour K, Tafreshi AR, Pahwa R, et al. Extended-Release Amantadine for Levodopa-Induced Dyskinesia. Expert Rev Neurother. 2019;19(4):293-299.
Dashtipour, K., Tafreshi, A. R., Pahwa, R., & Lyons, K. E. (2019). Extended-Release Amantadine for Levodopa-Induced Dyskinesia. Expert Review of Neurotherapeutics, 19(4), 293-299. https://doi.org/10.1080/14737175.2019.1592677
Dashtipour K, et al. Extended-Release Amantadine for Levodopa-Induced Dyskinesia. Expert Rev Neurother. 2019;19(4):293-299. PubMed PMID: 30892103.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Extended-Release Amantadine for Levodopa-Induced Dyskinesia. AU - Dashtipour,Khashayar, AU - Tafreshi,Ali R, AU - Pahwa,Rajesh, AU - Lyons,Kelly E, Y1 - 2019/03/20/ PY - 2019/3/21/pubmed PY - 2020/8/11/medline PY - 2019/3/21/entrez KW - Amantadine extended release KW - Parkinson’s disease KW - dopamine KW - glutamate KW - levodopa-induced dyskinesia KW - movement disorders KW - pharmacotherapy SP - 293 EP - 299 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 19 IS - 4 N2 - INTRODUCTION: Levodopa-induced dyskinesia (LID) is a significant impediment to the long-term use of levodopa for Parkinson's disease (PD). Relatively few studies exist that have described safe and effective therapy for LID. There is thus a significant need for therapy that can control LID to allow for greater sustainability of levodopa therapy. Amantadine extended release (ER) is currently the only FDA-approved medication for the treatment of LID. While other medications have demonstrated efficacy in treating the motor symptoms of PD, amantadine ER is the only one that has been shown, in several clinical trials, to reduce LID and reduce OFF time. Areas Covered: In this review, the authors present the findings of amantadine ER including its efficacy and safety. The authors also provide their expert perspectives on its use and its future prospects. Expert opinion: Several therapies are currently being used and studied for controlling LID, an unmet need in therapy for PD. Amantadine ER has potential to supplement levodopa therapy in PD and improve patient therapeutic outcomes. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/30892103/Extended_Release_Amantadine_for_Levodopa_Induced_Dyskinesia_ DB - PRIME DP - Unbound Medicine ER -